ClinicalTrials.gg
CompletedNCT04276220CACTuS2Updated Aug 15, 2025

Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery

An interventional study of Tenosynovial biopsy in Transthyretin Amyloidosis, Transthyretin Cardiac Amyloidosis and Wild-Type Transthyretin-Related (ATTR)Amyloidosis, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
109
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Denmark.

Started
2020
with 1 other
No phase
Only one
of the 11
Registered
5th of 11
by date
Lead sponsor
2 of 11
Steen Hvitfeldt Poulsen

Among the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, this one is one of 2 that started in 2020, is the only one with no phase, and was the 5th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

6 of the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, or all of them as a file.
02

Study summary

Patients above the age of 60 will be recruited at their carpal tunnel release surgery. Biopsies will be taken from the wrist and examined for the presence of amyloid protein. A amyloid-positive biopsy will refer the patients for cardiac examination including blod- and urine samples examined for transthyretin.

If the result of the cardiac examination is suspected cardiac amyloidosis, the patient will be referred for a diagnostic TC99-DPD scintigraphy. If the scintigraphy is positive, the patient will be referred for right heart catherization (RHC) and an exercise test.

Myocardial biopsies will be taken at the RHC and examined with electron microscopy and high resolution respirometry.

03

Conditions studied

  • Transthyretin Amyloidosis
  • Transthyretin Cardiac Amyloidosis
  • Wild-Type Transthyretin-Related (ATTR)Amyloidosis
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males above 65 years of age, females above 75 years of age.
  • Scheduled idiopathic carpal tunnel release surgery.
  • Informed written consent.

Exclusion criteria

Exclusion Criteria:

  • Operation by other indication, e.g.
  • Fracture
  • Ganglion
  • Known amyloidosis
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Other
    Tenosynovial Biopsy

    Diagnostic Test: Tenosynovial biopsy

Interventions

  • Diagnostic testTenosynovial biopsy

    Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.

06

What researchers measure

Primary outcomes

  1. Prevalence of wild-type transthyretin cardiac amyloidosis in patients undergoing surgery for idiopathic Carpal Tunnel Syndrome Surgery where biopsies from transverse carpal ligament stain positive for amyloid.

    We will examine the amyloid deposits prevalence in biopsies from the Carpal Tunnel and ATTRwt prevalence in an aged and predominantly male population operated for idiopathic Carpal Tunnel Syndrom. Diagnosis of wild-type cardiac amyloidosis will be determined by TC99-DPD scintigraphy, endomyocardial biopsy, or both. Biopsies will be examined using Congo Red staining and fluorescent light

    Time frame: Through study completion, 6 years.

Secondary outcomes

  1. Levels of transthyretin in blood and urine from patients with suspected wild-type transthyretin cardiac amyloidosis

    We will investigate the plasma and urine levels of different forms of TTR (total TTR, misTTR, and fragTTR) in patients with amyloid deposits in the transverse carpal ligament, patients subsequently diagnosed with ATTRwt-CM and in patients with already diagnosed ATTRwt matched age and gender. We will investigate whether the levels of TTR is higher among ligament amyloid positive patients that are subsequently diagnosed ATTRwt-CM as compared to those without ATTR-CM.

    Time frame: Has been added after study start, will run through study completion, 3 years.

  2. Comparing patients diagnosed with wild-type transthyretin cardiac amyloidosis due to screening with age and gender matched clinically diagnosed ATTRwt patients.

    Compare NAC-stage, NYHA-class, LVEF ect.

    Time frame: Through study completion, 6 years.

07

Study locations

1 site
  • Aarhus University Hospital
    Aarhus, Jylland 8200, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in May 2025, 61 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Feb 19, 2020
StartActual
Apr 1, 2020
Primary completionActual
May 21, 2025
CompletionActual
May 21, 2025
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04276220
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (Professor, DMSc, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Feb 19, 2020
Start date
Apr 1, 2020
Primary completion
May 21, 2025
Completion
May 21, 2025
Last update
Aug 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion